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Abstract
Despite mounting evidence that epigenetic abnormalities play a key role in cancer biology, their contributions to the
malignant phenotype remain poorly understood. Here we studied genome-wide DNA methylation in normal B-cell
populations and subtypes of B-cell non-Hodgkin lymphoma: follicular lymphoma and diffuse large B-cell lymphomas. These
lymphomas display striking and progressive intra-tumor heterogeneity and also inter-patient heterogeneity in their cytosine
methylation patterns. Epigenetic heterogeneity is initiated in normal germinal center B-cells, increases markedly with
disease aggressiveness, and is associated with unfavorable clinical outcome. Moreover, patterns of abnormal methylation
vary depending upon chromosomal regions, gene density and the status of neighboring genes. DNA methylation
abnormalities arise via two distinct processes: i) lymphomagenic transcriptional regulators perturb promoter DNA
methylation in a target gene-specific manner, and ii) aberrant epigenetic states tend to spread to neighboring promoters in
the absence of CTCF insulator binding sites.
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Introduction
Follicular lymphomas (FLs) and diffuse large B-cell lymphomas
(DLBCLs) are the most common non-Hodgkin lymphomas [1].
Follicular lymphomas represent a spectrum from low- to high-grade
tumors and, while predominantly diagnosed as indolent tumors,
progress to more aggressive lymphomas like DLBCL over the
course of several years [2]. DLBCLs are high-grade tumors that are
sub-classified based on gene expression profiling into a typically
chemo-responsivegerminal centerB-like(GCB) subtype anda more
refractory activated B-like (ABC) subtype (Figure 1A) [3]. Although
FL and DLBCL have markedly distinct clinical phenotypes, they
both originate from mature B-cells transiting the germinal center
(GC) reaction. When resting naı ¨ve B-cells are activated by exposure
to T-cell dependent antigens, they migrate within lymphoid follicles
and initiate massive clonal expansion while simultaneously under-
going somatic hypermutation and class switch recombination.
Genetic defects arising as a byproduct of this immunoglobulin
affinity maturation process are believed to give rise to FLs and
DLBCLs [4]. Consistent with this hypothesis, genomic resequen-
cing studies identified a large number of mutations occurring in FL
and DLBCL. While it is known that FLs accumulate new mutations
as they progress, the underlying cause of the different phenotype of
de novo FL and DLBCL, which share many of the same mutant
alleles, remains unclear. Emerging data suggest that epigenetic gene
regulation through cytosine methylation is perturbed in FLs and
DLBCLs, yet very little is known about how aberrant DNA
methylation contributes to the disease phenotype, the genomic
features of epigenetic defects in these tumor types, and mechanisms
through which these defects occur. Recently we demonstrated that
DNA methylation patterning plays a key role in hematopoietic
development [5] and that DNA methylation and expression
signatures define molecular subtypes of diffuse large B-cell
lymphomas [6]. Here, we hypothesized that direct comparison of
DNA methylation patterning in normal B-cells, FLs and DLBCLs
would provide clues about gene deregulation during lymphoma-
genesis and explain the nature of the different clinical behavior of
these lymphoma subtypes.
PLOS Genetics | www.plosgenetics.org 1 January 2013 | Volume 9 | Issue 1 | e1003137Results/Discussion
DNA methylation heterogeneity is associated with
increasing disease aggressiveness
We examined the DNA methylation profiles of normal naı ¨ve B-
cells (NBC, 8 samples), normal germinal center B-cells (NGC, 10
samples), follicular lymphomas (FL, 8 samples), germinal center B-
like DLBCLs (GCB, 39 samples), and activated B-like DLBCLs
(ABC, 18 samples) (Figure 1A, Methods and Text S1, Module 1;
Table S1) using the HELP assay [7] and custom-designed
NimbleGen microarrays with probesets representing .50,000
CpGs corresponding to regulatory regions of roughly 14,000
human genes. In the HELP assay, the normalized array signal
intensity corresponds to the degree of methylation associated with
Author Summary
Follicular lymphomas and diffuse large B-cell lymphomas
are the most common non-Hodgkin lymphomas. Although
these diseases share many mutant alleles, the underlying
cause of the different phenotypes remains unclear. We
show that direct comparison of DNA methylation pattern-
ing provides insights about gene deregulation during
lymphomagenesis and explains the nature of the different
clinical behavior.
Figure 1. Methylation variation in normal and lymphoma samples. (A) Summary of the normal and lymphoma samples used in this study. (B)
Histogram representation of DNA methylation score (M-score, horizontal axis) and frequency (vertical axis). Positive M-scores represent hypo-
methylation while negative scores represent hyper-methylation. The DNA methylation distributions of samples are shown using the same color code
as in panel A. The methylation patterns of NBC are bimodal, where the positive node represents hypo-methylation and the negative node represents
hyper-methylation. The proportion of promoters with intermediate M-score (around zero), which represents high intra-sample variation, increases for
lymphoma categories with increased disease severity. (C) The histogram represents the frequency distribution of inter-quartile ranges (IQR) of theM -
scores per probeset for normal and diseased samples. The vertical axis represents the frequency of probesets and the horizontal axis represents the
IQR. High IQR values indicate high inter-sample variation, and the proportion of such promoters increases for lymphoma categories with increased
disease severity. (D) The scatter plot reflects the joint distribution of M-scores and IQR, which represent intra- and inter-sample variation, respectively,
per probeset for normal B-cells and lymphoma categories. The color intensity is proportional to the density of points on the graph. High inter-sample
variation is also associated with high intra-sample variation. The distribution of points becomes progressively broader and more smear-like in
lymphoma samples vs. normal B-cells. The colors are the same as in (A).
doi:10.1371/journal.pgen.1003137.g001
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or negative normalized signal intensity indicates that the respective
CpGs are either unmethylated or methylated (Figure S4). In
contrast, intermediate probeset signal intensity indicates that a
fraction of cells within the sample are unmethylated while others
are methylated, thus reflecting the heterogeneity of methylation.
We performed technical validation for the HELP array and
validated DNA methylation profiles of six DLBCL samples using
orthogonal base-pair resolution quantitative bisulfite sequencing
based assays: ERRBS and MassARRAY assays (Text S1, Module
1 and Figures S5, S6, S7, S8). Overall mapping of probesets
according to their positions along the human chromosomes
indicated that sites of hypo- and hyper-methylation were
distributed across all chromosomes in both normal and lymphoma
samples (Text S1, Module 1, and Figure S9). However, we noted a
higher abundance of intermediate methylation states in lympho-
mas and hypothesized that epigenetic heterogeneity might
contribute to the clinical features of the disease.
In order to address this question we derived two parameters:
(i) The ‘‘M-score’’, a measurement of intra-sample DNA
methylation heterogeneity. The M-score specifically reflects
the degree of methylation at a given probeset and thus the
uniformity with which specific CpGs are methylated or
unmethylated; an intermediate score (around zero) reflects
the presence of balanced hypo- and hyper-methylated CpGs
within the cells of a sample and thus high intra-sample
variation (Figure 1B).
(ii) The inter-quartile range (IQR) of the M-score, a measure-
ment of inter-sample heterogeneity, derived from comparing
the differences in signal intensity of given probesets across
different samples of the same normal or tumor cell type. The
IQR reflects the extent of inter-sample methylation variation
by measuring the spread of the distribution of M-scores
(Figure 1C).
Using these indicators for normal cell types, we observed a
strong bimodal distribution of probeset intensities, indicating that
the vast majority of gene promoter CpGs were predominantly
either unmethylated or methylated within the cells of a sample, as
represented by the two modes at positive or negative M-scores,
respectively (Figure 1B). This observation is consistent with
previous studies noting the bimodality of DNA methylation
distributions in normal tissues [7,9]. In contrast, the distribution
of DNA methylation in lymphoma samples was significantly
different from those of normal cells (Figure 1B; Kolmogorov-
Smirnov test between pairs of normal and lymphoma samples;
FDR corrected p-value,2.2610
216). All lymphoma subtypes
showed a significantly greater proportion of probes with an
intermediate M-score, indicating increased intra-sample variation,
and most notably, such variation increased progressively from FL
to GCB to ABC DLBCLs. This intra-sample variation was not due
to sample purity, which was high for both lymphoma and normal
(NBC, NGC; .90% purity) samples as confirmed by flow
cytometry, and was not accounted for by differences in cellularity
among the samples [10] (Text S1, Module 1). In order to prove
that intra-sample variation is an inherent feature of neoplastic
transformation, rather than a technical artifact or a result of a
confounding biological factors, we performed analysis controlling
for (i) copy number variations using SNP data (Figure S1), (ii)
sample purity using % purity data (Figure S3), (iii) exclusion of low
signal-to-noise ratio probes from the analysis (Figure S4), (iv)
differences in mitotic rate using cell line data with known doubling
times (Figure S11; Table S2), and (v) potential age differences
between controls and DLBCL patients (Figure S12). Finally, we
validated the observation of increasing intra-sample heterogeneity
in DLBCLs using the MassARRAY and ERRBS orthogonal
assays, which supported our findings (Text S1, Module 1, and
Figures S5, S6, S7).
Likewise, we then found that the IQR values, which represent
inter-sample variation, were small in normal B-cell controls, but
again progressively increased in FL and the GCB and ABC
subtypes of DLBCL (Figure 1C; Mann-Whitney test between pairs
of normal and lymphoma tissues; FDR corrected p-value
,2.2610
216). We also obtained consistent results using alternative
approaches to profile methylation changes as well as an alternative
definition of inter-sample variation (Text S1 Module 1, Figure
S10). Since higher-grade lymphomas are known to display
genomic instability, we verified that the observed differences in
methylation in lymphomas were not due to gain or loss of genomic
material by controlling for copy number alterations using SNP
data from the same patients (Text S1, Module 1, and Figure S1).
Variability was also independent of whether the probes were
localized in CpG islands or not (Text S1, Module 2; Figure S13).
We found that the promoter regions with high CpG density
usually were more hypo-methylated than others, as observed using
both HELP and ERRBS assays, but that the CpG density did not
affect patterns of inter-sample variation (Text S1, Module 2;
Figures S14, S15 S16). Notably, the probes with high intra-sample
variation (i.e., M-scores near zero) were also likely to have high
inter-sample variation (i.e., high IQR) in normal and lymphoma
samples (Figure 1D); this finding is consistent with the identifica-
tion of variable CpGs in solid tumors [11].
In summary, since FLs are diagnosed most often as indolent
tumors while GCB and ABC DLBCLs have progressively worse
prognosis, our findings suggest that the extent of intra-and inter-
sample variation in DNA methylation increases with disease
aggressiveness. Based on our cell line data (Text S1, Module 1, and
Figure S11) it is unlikely that the greater epigenetic heterogeneity
in more aggressive tumors is a reflection of higher proliferative
rates that lead to stochastic variation in the DNA methylation
distribution. Alternatively, heterogeneity could be related to loss of
function of specific epigenetic regulators that normally tightly
control DNA methylation patterns. Either way, epigenetic
diversity could foster the survival of subpopulations of lymphoma
cells after exposure to cytotoxic drugs, thus contributing to the
greater risk of relapse in ABC DLBCLs. We found that DNA
methylation diversity initiates within NGC, which are more
heterogeneous than NBCs (Figure 1B–1D), which is consistent
with recent findings [10]. All three lymphoma subtypes originate
via different molecular and likely epigenetic mechanisms from a
common precursor – germinal center B-cells. Each subtype is
characterized by a different extent of epigenetic heterogeneity,
which likely reflects different mechanisms of lymphomagenesis.
Epigenetic diversity might then cooperate with somatic mutations
in predisposing NGC towards malignant transformation.
The patterns of aberrant DNA methylation predict
patient survival
It is not known whether alterations in DNA methylation
patterning are associated with clinical outcome in lymphomas.
Using a phylogenetic clustering approach [12], which arranges
samples according to their distance in methylation patterning from
that of undifferentiated cells, we found that genome-wide DNA
methylation undergoes progressive changes from bone marrow
CD34+ hematopoietic progenitor cells to NBC and NGC, FL and
then DLBCL (Figure 2A). This finding reflects the ontogeny of
normal B-cell development, the origin of B-cell lymphomas in
Aberration in DNA Methylation in B-Cell Lymphomas
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then performed a Kaplan-Meier analysis using a methylation
heterogeneity score derived from the distances of the methylation
pattern of each tumor to that of the methylation pattern of NGC
(Text S1, Modules 1 and 3; Figures S18, S19; Tables S3, S4). Cox
models incorporating the International Prognostic Index (IPI) [13]
and methylation heterogeneity score as covariates were then
utilized for stratification of patients into high- and low-risk groups,
depending on whether their estimated risk scores were above or
below the cohort median. Analyzing the GCB and ABC samples
together, we found that the methylation heterogeneity score
improved the concordance [14] of the predictions of the IPI from
0.64 to 0.7 (DC 0.06; 95% CI 20.08–0.20; Text S1, Module 3)
and yielded a significant risk stratification (HR=3.85, p,0.03;
Figure 2B). Thus, we found that the extent of aberrant
methylation, as measured by the distance of a patient sample in
terms of its methylation patterning from that of normal B-cells, is a
significant predictor for survival: disease types with high intra-
sample methylation variation have a poor prognosis and short
survival while disease types with low intra-sample methylation
variation have a good prognosis and long survival. Increased
epigenetic heterogeneity may reflect the presence of diverse tumor
cell populations in the patient, which in turn increases the risk of
resistance and of the emergence of more aggressive clones, thus
leading to poor prognosis. In a complementary analysis, we
grouped the FL samples according to grade and found that DNA
methylation patterning becomes increasingly heterogeneous with
an increase in disease severity in FL (Text S1, Module 3; Figure
S20). Taken together, our results demonstrate that the landscape
of epigenetic DNA modifications is associated with the degree of
neoplastic transformation and aggressiveness of a tumor.
Aberrant cytosine methylation patterning is dependent
on chromosomal regions and local gene density
To determine whether genomic features direct the aberrant
cytosine methylation distribution in lymphomas, we examined
DNA methylation diversity at the chromosomal regional level. In
order to facilitate the visualization of intra-sample (M-scores) and
inter-sample (IQR) heterogeneity in DNA methylation, we
transformed the histograms shown in Figure 1B and 1C into a
‘‘violin’’ plot format (Figure 3A). Chromosomes were separated
into telomeric, centromeric, and intermediate regions. We
observed that centromeric regions were hyper-methylated in
normal cells but exhibited a gradual loss of methylation in
lymphomas (Figure 3B). Intermediate chromosomal regions
displayed increasing intra-sample variation with disease severity,
i.e. NBC,NGC,FL,GCB,ABC (p-value for NBC-FL,
NBC-GCB and NBC-ABC pairs,2.2610
216; Kolmogorov-Smir-
Figure 2. The extent of DNA methylation aberration is predictive of patient survival. (A) Phylogenetic tree, as estimated based on the
correlation of group-averaged M-scores. Departure from normal methylation patterns is correlated with disease severity of the lymphoma samples.
(B–C) Kaplan-Meier curves for risk groups defined according to their methylation distance score (i.e. distance from normal B-cells), which reflects how
different a sample’s methylation profile is from that of NBC or NGC, for all DLBCL (GCB and ABC) samples. (B) Multivariate analysis with the
International Prognostic Index (IPI) and distance to NBC. (C) Only IPI.
doi:10.1371/journal.pgen.1003137.g002
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PLOS Genetics | www.plosgenetics.org 4 January 2013 | Volume 9 | Issue 1 | e1003137Figure 3. Genome-wide patterns of aberrant methylation. (A) Graphical explanation of how the distribution of M-scores and IQR are
transformed into violin distribution plots to enable more efficient visualization and comparison on intra- and inter-sample variability. (B) Distribution
of the methylation score (M-score, left) and inter-quartile ranges (IQR, right) at probesets in centromeric, telomeric, and intermediate regions for
normal and diseased tissues. Bar width is proportional to the number of data points, and the colors are the same as in Figure 1A. (C) Distributions of
M-score (left) and IQR (right) are shown for gene-poor, gene-rich, and intermediate regions.
doi:10.1371/journal.pgen.1003137.g003
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the initial analysis is localized in these regions. All three regions
displayed an overall tendency towards greater inter-sample
variation in lymphoma cells compared to normal cells throughout
all three chromosomal regions. These results were also validated
using the ERRBS assay (Text S1, Module 2; Figure S17).
To investigate whether disruption of cytosine methylation is
associated with gene density, we divided the genome into non-
overlapping windows classified as gene-rich, intermediate, or gene-
poor (Methods section). We found that in normal B-cells, gene-rich
regions displayed a bimodal methylation pattern, while gene-poor
regions were mostly hyper-methylated. This distribution was
perturbed in lymphomas, which exhibited increased intra-sample
variation in gene-rich regions, while gene-poor regions displayed
progressive hypo-methylation compared to normal B-cells
(Figure 3C). Inter-sample variation was low in normal cells in
both gene-poor and gene-dense regions, but significantly increased
in the lymphoma subtypes for both categories (FL: p-value
,1610
23, GCB and ABC: p-value,1610
210; Mann Whitney
test). Our findings were robust even after excluding centromeric
and telomeric regions (Text S1, Module 4; Figure S21). Taken
together, our results show that abnormal methylation patterns in
lymphoma samples depend on chromosomal regions and local
gene density. This differential aberration in gene-poor versus gene-
rich areas suggests that these changes are not random, but are
directed by genomic or epigenomic modifiers.
Aberrant DNA methylation patterning spreads locally
between genes but is limited by CTCF
We next focused at the level of specific genes and their impact
on DNA methylation of neighboring genes (Figure 4A). We found
that 3,414 and 2,044 probesets were significantly hyper- and hypo-
methylated in ABC vs. NGC specimens, respectively (FDR-
corrected p-value,5.0610
23, Text S1, Module 5). For each of
these hypo- and hyper-methylated promoters (denoted as ‘‘i’’ in
Figure 4A and 4B), we investigated their neighboring promoter
probesets (‘‘i+1’’, ‘‘i21’’, ‘‘i+2’’, ‘‘i22’’ up to ‘‘i25’’ and ‘‘i+5’’).
For both hyper- and hypo-methylated promoter probesets, we
found that their neighboring promoter probesets also displayed a
change in methylation in the same direction (Figure 4B), and that
this effect weakened with increasing distance, i.e. decayed from i+1
(or i21) to i+5 (or i25). Therefore, when a promoter displayed
aberrant hypo- or hyper-methylation in lymphoma samples, their
neighboring promoters were also likely to follow a similar trend.
For instance, when the i-th promoter probeset was aberrantly
hypo-methylated (DM-score.0), then the i61 (i.e. i+1 and i21)
promoter probesets were also significantly aberrantly hypo-
methylated (DM-score.0; p-value: 4.56610
25); and when the
i-th promoter probeset was aberrantly hyper-methylated (DM-
score,0), then the i61 positions were also significantly aberrantly
hyper-methylated (DM-score.0; p-value: 3.11610
23). This effect
was stronger for hypo-methylated loci. For instance, when the i-th
probeset was aberrantly hypo-methylated (DM-score.0), then the
s65 (i.e. i+5 and i25) positions were also significantly aberrantly
hypo-methylated (DM-score.0; p-value: 3.01610
23), but the
effect was not significant in the case of aberrant hyper-methylation
(DM-score,0; p-value.0.05 at i65 positions). We then found that
the aberrantly hypo-methylated promoters, but not the hyper-
methylated ones, generally displayed a greater extent of inter-
sample variation among ABC lymphomas (Figure 4C). Our results
were similar for the other lymphoma subtypes (Text S1 Module 5;
Figures S22 and S23), and at par with published reports that local
DNA methylation and histone modification (H3K9me3) patterns
spreads to neighboring regions. [15–17] Thus it is likely that
abnormal promoter methylation, especially hypo-methylation,
tends to spread to neighboring promoters along the chromosomes;
however, at this stage we cannot rule out other possibilities.
The transcriptional repressor CTCF contributes to the organi-
zation of chromatin domains and the spatial delimitation of
epigenetic marks [18]. Hence, we investigated whether CTCF was
associated with the DNA methylation status of genes in normal
and lymphoma cells. Overlaying published genome-wide CTCF
ChIP-seq data [18,19], we found that promoters in CTCF-binding
site (BS)-poor regions were usually hyper-methylated in normal B-
cells, but hypo-methylated in lymphomas (FL, GCB and ABC)
(Figure 5A–5B). There was little inter-sample variation in normal
Figure 4. Spreading of aberrant methylation to neighboring
probesets in the ABC samples. (A) A schematic representation of
how the genome was divided into blocks of genes to study spreading
of altered DNA methylation. (B–C) Analysis of spreading of aberrant
methylation within genomic neighborhoods. Loci ‘‘i’’ represent
probesets that are significantly hypo- (black) or hyper-methylated
(grey) in lymphoma samples compared to normal tissues, and loci ‘‘i6j’’
represent both the (i+j)-th and (i2j)-th neighbors of those probesets.
For instance, when we focused on probeset #10 (i.e. i=10), we
analyzed spreading of aberrant methylation at probesets #5, 6, 7, 8, 9,
11, 12, 13, 14 and 15. Panel B displays the change in methylation states
while panel C shows the change in IQR (variability between samples).
doi:10.1371/journal.pgen.1003137.g004
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lymphoma subtypes, CTCF-BS-poor regions displayed significant-
ly greater inter-sample variation than CTCF-BS-dense regions (p-
value for NBC: 1.040610
26; NGC: 6.656610
27; FL: 2.9610
213;
GCB: 1.367610
211; ABC: ,2.2610
216, Mann Whitney test).
Our findings were robust even after excluding centromeric and
telomeric regions (Text S1, Module 6; Figure S24). These data
suggest that CTCF-BS-poor regions are more susceptible to
epigenetic deregulation.
Since CTCF can establish boundaries between genomic
regions, we tested whether it might affect DNA methylation
spreading between loci and whether this function was perturbed in
lymphomas. We divided the probesets into two groups: those in
which neighboring promoter probesets were separated by at least
Figure 5. The insulator factor CTCF prevents spreading of aberrant methylation. (A) Methylation heterogeneity depends on the density of
CTCF-binding sites. Methylation state (M-score, left) and inter-sample methylation variation (IQR, right) are shown for CTCF-BS-poor, CTCF-BS-rich,
and intermediate regions. (B) Spreading of aberrant methylation from genomic position ‘‘i’’ to ‘‘i61’’ (i.e. two neighboring sites) when at least one
CTCF-BS is present (black vertical dotted line) and when no CTCF-BS is present (light grey vertical dotted line) between ‘‘i’’ and ‘‘i61’’, for aberrant
hypo-methylation (two left panels) and aberrant hyper-methylation (two right panels). The presence of CTCF-BS more efficiently restricts the
spreading of aberrant hypo-methylation. (C) A schematic overview showing spreading of abnormal methylation in the absence of CTCF-binding sites
in genomic neighborhood.
doi:10.1371/journal.pgen.1003137.g005
Aberration in DNA Methylation in B-Cell Lymphomas
PLOS Genetics | www.plosgenetics.org 7 January 2013 | Volume 9 | Issue 1 | e1003137one CTCF-BS, and those in which neighboring promoter
probesets were not separated by any CTCF-BS. First, focusing
on the promoters hypo-methylated in ABC versus NGC, we found
that promoter pairs not containing intervening CTCF–BS
displayed greater spreading of aberrant hypo-methylation from
one promoter (probe set i) to the neighboring promoters (probe
sets i+1 and i21) compared to those that had one or more
intervening CTCF-BS (Figure 5B, comparing probe sets i+1, i21
between the two groups, p-value=2.2610
28, Mann Whitney test).
In contrast, we did not observe any impact of CTCF on genes with
hyper-methylation in DLBCL (Figure 5B, p-value.0.05 at
probesets i61, Mann Whitney test). We obtained similar results
for the FL and GCB samples and using the ERRBS assay instead
of the HELP assay data (Text S1, Module 6; Figures S25, S26).
Thus, CTCF is suspected to play a gatekeeper role in the
spreading of aberrant hypo-methylation among genes in DLBCL
(Figure 5C), although more work is necessary to rule out other
possibilities.
Lymphomagenic regulatory proteins contribute to
aberrant DNA methylation patterning in DLBCL
We then investigated potential factors associated with the
abnormal DNA methylome in lymphomas. We first investigated
whether in general, there was an association between promoter
methylation status and the expression of the same gene and found
a positive correlation (Text S1, Module 7), which suggests that
genes with a loss of promoter methylation were likely to experience
increased expression. We then obtained genomic localization data,
detected by genome-wide CHIP-chip or CHIP-seq studies, of four
master regulators of lymphoid differentiation and lymphomagen-
esis: BCL6 [20], EZH2 [21], MYC (newly reported herein), and
AICDA [22], and overlaid promoter methylation information
(Text S1, Module 7; Figures S27, S28, S29). BCL6 is a
transcriptional repressor that is expressed in NGCs and also in
most DLBCLs and FLs [23], and its constitutive expression is
known to drive malignant transformation of NGCs [24]; EZH2 is
a Polycomb repressor protein also expressed in NGC [25] that is
highly expressed in most DLBCLs [26] and is sometimes targeted
by gain of function mutations [27]; and the MYC oncogene, is
aberrantly expressed in DLBCLs, often through chromosomal
translocations [20,28]. AICDA is a cytosine deaminase that
mediates single- and double-strand DNA breaks during somatic
hypermutation and class switch recombination [29]. We first
investigated the extent of change in the DNA methylation status of
the BCL6 and MYC loci, including the surrounding genes, in
lymphoma samples compared to that in the NBC samples, and
found that both BCL6 and MYC loci experienced loss of promoter
methylation in lymphoma samples compared to normal samples
(Text S1, Module 7; Figure S29). Furthermore, we found that the
target gene promoters of MYC, BCL6 and EZH2 were hypo-
methylated in normal B-cells and became increasingly hyper-
methylated in lymphoma samples (Figure 6A–6C; p-value
,1610
24 for all three cases; Mann-Whitney test). Gain of
methylation at the promoters of the target genes of MYC,
BCL6, and EZH2 in lymphomas was significantly higher than that
at the promoters of other genes (Mann Whitney test, p-
value,1610
25 in each case). Since BCL6 and EZH2 are
transcriptional repressors, accumulation of DNA methylation
may reflect their constitutive activity at their targets in lymphoma
cells. Notably, a previous report showed that EZH2 and H3K27
are mostly mutually exclusive with DNA methylation in NGC B-
cells, but that this opposing relation is disrupted in DLBCL [21].
The reason for MYC targets acquiring hypermethylation is not as
clear, but it is notable that the MYC and BCL6 ChIP-on chip
binding patterns are highly overlapping (data not shown). In
contrast, target genes of AICDA, such as BRCA2, GATA1 and
LMO1 [22], displayed a loss of bimodality (Figure 6D). However,
hypomethylation of promoters of AICDA target genes was not
immediate apparent, perhaps indicating disruption or variability in
AICDA binding to the genome in malignant cells. Nevertheless,
AICDA expression was associated with a loss of DNA methylation
at a genome-wide scale, as discussed in the following section in
detail, which is consistent with the role of AICDA in demethyl-
ation [6,30,31]. AICDA plays a role in gene demethylation
downstream of TET family protein-mediated hydroxylation of
methylcytosine [30]. Moreover, we recently reported that genes
that are hypo-methylated in NGC B-cells tend to be known direct
targets of AICDA [10]. Collectively, aberrant DNA methylation in
lymphomas is related in part to the action of constitutively
expressed lymphomagenic regulatory factors during lymphoma-
genesis (Figure 6E).
We next used an independent approach, integrating DNA
methylation and gene expression profiling data in a subset of our
cases, to identify factors driving or associated with the aberrant
lymphoma methylome. First, we focused on a set of genes:
DNMT3A, DNMT3B, DNMT3L, MYC, BCL6, AICDA,
MBD4, MBD6, CD79A, CD79B and MECP2 – which include
DNA methyltransferases, methyl-CpG binding domain proteins,
as well as signaling and transcription factors involved in lymphoid
differentiation and lymphomagenesis. We investigated whether the
expression levels of these genes correlated with genome-wide
aberrant DNA methylation patterns in DLBCL samples (see Text
S1, Module 7 for details of the method). We found the following
trends (Figure 7A): (i) the BCL6 expression level was significantly
correlated with aberrant hyper-methylation at a genome-wide
scale (p-value,0.05), which is consistent with a transcriptional
repressor role of this gene, and (ii) expression levels of AICDA and
CD79A were significantly correlated with aberrant hypo-methyl-
ation at a genome-wide scale (p-value,0.05 in both cases). This
finding was significant given the role of AICDA in demethylation,
as noted above [6,30,31]. The association was not significant for
other genes in the list for our dataset. Larger patient cohorts will
be necessary to test those cases systematically.
Some the above factors, such as DNMT3B, are associated with
the maintenance of methylation in simple repeat sequences [32].
Indeed, overlaying DNA repeat sequence information, we found
that both low-complexity repeats and simple repeats exhibited
hypo-methylation in normal cells, but displayed an increasing
extent of hyper-methylation in lymphoma samples (Text S1,
Module 8; Figure S30). Note that the effect size of expression levels
of each of the 11 genes, including DNA methyltransferases, is
relatively modest; this may be at least partly due to the fact that
these modifier genes influence the epigenetic state of their target
genes by the recruitment of other enzymes or cofactors, and that
the lymphoma samples show a high level of intra-sample variation.
A completely unbiased genome-wide analysis exploring whether
other genes on the expression array showed significant associations
with the aberrant methylation pattern in lymphomas yielded a list
of candidates provided in Figure 7B (see Text S1, Module 7 for
details). Interestingly, some of the top genes are known epigenetic
modifiers. For instance, the top candidate of the list, WHSC1L1, is
a known histone methyltransferase and plays a key role in
chromatin integrity [33–35]. Other top hits are important for the
genomic and epigenomic integrity of the cell, such as NAP1L2,
which promotes histone acetylation [36], and SMC6, which
regulates chromosomal stability [37,38]. Many of these genes are
known epigenetic modifiers, downstream targets or co-factors of
the shortlisted genes described in the paragraph above, while
Aberration in DNA Methylation in B-Cell Lymphomas
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methylation patterning in DLBCLs. Systematic characterization of
these candidates will be pursued further in forthcoming work.
Conclusions
Through integrative analysis of DNA methylation, copy
number variation, genomic sequence, gene expression and
genomic localization data, our study provides insights into the
architecture and biology of aberrant DNA methylation patterning
in a human malignancy. Based on these analyses, we report three
key findings: (a) DNA methylation exhibits considerable hetero-
geneity, both within individual lymphoma samples and between
patients, and the degree of heterogeneity and departure from the
DNA methylation pattern of normal B-cells correlates with disease
severity and patient survival, (b) these abnormal methylation
patterns are not randomly distributed but instead associate with
chromosomal regions, local gene density, and the methylation
status of neighboring genes, and (c) the pattern of DNA
methylation abnormalities is at par with the effects of at least
two distinct processes: i) lymphomagenic transcriptional regula-
tors, such as BCL6 and EZH2, perturb DNA methylation in a
target gene-specific manner; and ii) aberrant methylcytosine
marks, especially promoter hypo-methylation, tend to spread to
neighboring promoters in the absence of insulator elements such as
CTCF. We propose that focal aberrant hyper- and hypo-
methylation via target-specific recruitment of master regulators
and non-specific spreading of aberrant methylation drives the
generation of epigenetic abnormalities in follicular lymphoma and
DLBCL. While our results themselves cannot pinpoint causality,
they are consistent with emerging reports that highlight the roles of
lymphomagenic transcriptional regulators [23,24,26] and that
DNA methylation patterns tend to spread in a genomic
neighborhood [15–17]. Recently, Lai et al. showed that BCL6
expression is maintained during lymphomagenesis in part through
DNA methylation that prevents CTCF-mediated silencing [39],
and our results confirm their conclusions. The fact that epigenetic
diversity is first observed in NGC B-cells further suggests that
epigenetic heterogeneity may originate in these rapidly dividing
Figure 6. Genomic localization of transcriptional regulators and AICDA associates with sites of aberrant DNA methylation. (A–D)
Methylation heterogeneity of promoters of genes that are targets of master regulators. The panels display the distribution of methylation scores (M-
scores) for promoters of target genes of (A) BCL6, (B) MYC, (C) EZH2, and (D) AICDA. (E) A schematic overview showing targeted abnormal promoter
methylation by master regulators such as MYC, BCL6, EZH2 and AICDA in the lymphoma subtypes.
doi:10.1371/journal.pgen.1003137.g006
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Since epigenetic abnormalities increase with disease aggressiveness
and are a predictor of patient survival, clonal epigenetic diversity
and evolution may increase the survival advantage of lymphoma
cells, leading to more aggressive and chemo-resistant tumors.
Heterogeneity in DLBCL DNA methylation patterning does not
preclude the co-existence of subtype-specific DNA methylation
profiles, in which specific genes are differentially methylated.
Indeed, we previously observed that ABC and GCB DLBCLs
feature distinct and specific DNA methylation signatures, involv-
ing genes of potential functional significance, most notably
including hypermethylation of a TNFa gene network in ABC
DLBCLs [6]. These signatures represent a core of stably affected
loci within the larger context of more variable DNA methylation
disruption as reported herein. While previous studies including
ours aimed at identifying key genes and pathways dysregulated in
lymphomas, here we add another dimension to these studies by
highlighting the implications of epigenetic heterogeneity at a
genome-wide scale, and also the complex interaction between
master regulators and insulator elements that contribute to
establishing an abnormal methylome during lymphomagenesis.
Our approach can be used to analyze other tumor types and
delineate the contribution of aberrant methylation patterning to
the development of human cancers.
Methods
Sample collection
Samples used in the study included naı ¨ve B-cells (NBC; 8
samples), normal germinal center B-cells (NGC; 10 samples),
follicular lymphoma (FL: grades 1 and 2 representing lower grade
lymphoma than Diffuse Large B-cell Lymphoma (DLBCL); 8
samples), germinal center B-cell-like DLBCL (GCB: DLBCL with
better prognosis; 39 samples), and activated B-cell-like DLBCL
(ABC: DLBCL with worse prognosis; 18 samples). All FL and
DLBCL samples used in the study were selected based on their
high content of neoplastic cells from primary diagnostic material
preceding treatment and were obtained by the Vancouver Cancer
Center in British Columbia, Canada. The FL and DLBCL
samples represent soft tissue biopsy material. The percent of
neoplastic cells in the biopsy was determined based on pathologic
evaluation using morphologic criteria and immunohistochemical
characteristics of the neoplastic cells (expression of CD79B, CD20,
BCL2, CD10, CD43, BCL6 antigens).The use of human tissue
was in agreement with IRB of the Vancouver Cancer Center and
Weill Cornell Medical Center. Primary NBC and NGC B-cells
were purified from reactive human tonsillar specimens. Tonsils
were minced on ice and mononuclear cells were isolated using
Histopaque density centrifugation. All washes were performed in
PBS/2% Bovine Serum Albumine/2% EDTA. All antibodies
were used at 1:100 dilution in cold PBS and staining was done for
10 min on ice, followed by 3 washes. The B-cell populations were
separated using the AutoMACS system (Milteny Biotec, Auburn,
CA) using the ‘‘posselD’’ program. In brief, NBC cells were
separated using depletion of GC cells, T-cells, plasma and memory
cells (CD10, CD3, CD27), followed by enrichment for IgD+ B-
cells; GCB cells were separated by positive selection with CD77
(anti-CD10: BD Biosciences cat# 555373 Lot 59624, anti-CD3:
BD Biosciences cat# 555332 Lot 59347, anti-CD27: BD
Biosciences cat# 555439 Lot 71274, anti-CD77: Serotec cat#
MCA579 Batch 180510, anti-IgD: BD Biosciences cat# 555778
Lot 58641). While the tissue environment of the collected normal
and lymphoma cells (e.g. cytokine exposure level) differ, this is
unlikely to bias our analyses. All NBC and NGC samples yielded a
purity of .90%. For patient characteristics (Table S1) see
Shaknovich et al. [6] and GEO number GSE23967.
HELP assays and analysis of DNA methylation data
We assayed genome-wide patterns of promoter methylation
using HELP assays and custom-designed oligonucleotide arrays.
HELP assays were performed based on the standard protocol [7].
One mg of high molecular weight genomic DNA was digested with
HpaII and MspI (NEB, Ipswich, MA), digestion products were
extracted with phenol-chloroform and resuspended in 10 mM
TRIS-HCl pH8, after which they were subjected to ligation of
HpaII adapter using T4 DNA Ligase. This approach was followed
by PCR amplification and labeling of HpaII and MspI digestion
products and co-hybridization to custom NimbleGen HELP
Figure 7. Genes associated with aberrant DNA methylation patterns B-cell lymphoma. (A) List of genes potentially associated with
aberrant methylation patterns in DLBCL. Boxplots visualize the distribution of Pearson correlation coefficients of primary variable (expression level of
a candidate gene) and the fitted variables (DM of promoters). The numbers on top represent the summarized quantity R
2, i.e. statistical variance in
the fitted variable explained by the primary variable (in percent). See Text S1, Module 7 for more details. Statistically significant R
2 values (p,0.05) are
marked with an asterisk. (B) List of the top 10 genes with highest R
2 the unbiased genome-wide analysis. See Text S1, Module 7 for more details.
doi:10.1371/journal.pgen.1003137.g007
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design was previously published and represents .50,000 CpGs
corresponding to 14,000 promoters [6,7].
Data processing was performed using the published HELP
pipeline [40]. Intra- and inter-array normalization was performed
by subtracting mean random probe intensity separately within
HpaII and MspI channels, after which quantile normalization was
performed within each channel independently. Quantile normal-
ized log2(HpaII/MspI) values, denoted as M-scores, were subse-
quently used for all further analysis. The probes whose intensity of
Msp1 channel was less than 2.5 mean absolute standard deviations
from the mean of log2(Hpa2/Msp1) of random probes were
considered failed and removed from the analysis. Since the Msp1
channel served as an internal control, it allowed us to remove the
probes that had low intensities due to genomic deletions, thus
avoiding false positives for hypermethylation. We also calculated
the inter-quartile range (IQR) of the M-scores between the
samples within the same normal or disease group at a given locus
to reflect inter-sample methylation diversity. The analysis was
based on the Human Reference Genome version hg19 [41] and
the list of human protein-coding genes was obtained from Ensembl
v59 [42]. HELP arrays for DLBCLs can be found in GEO
number GSE23967 and for CD34+ cells in GEO number
GSE18700. NBCs, NGCs and FLs data is pending GEO accession
number.
Phylogenetic tree analysis
HELP methylation data for CD34+ hematopoietic progenitor
cells was obtained from the NCBI Geo database (GSE18700).
HELP was performed in the same manner as the normal (NBC
and NGC) and lymphoma (FL, GCB and ABC) samples,
hybridized on the same methylation microarray and normalized
using the same protocol together with the normal and lymphoma
samples. Only promoter methylation probes without missing
values were considered for further analysis. M-scores were
averaged for each group (CD34+, NBC, NGC, FL, GCB and
ABC) on each probe. Pairwise distances between groups were then
calculated with the Pearson correlation distance on the group-
averaged M-scores. This approach was repeated 1000 times, with
bootstrapping of promoter methylation probesets and samples.
Then, phylogenetic trees were constructed using the FastME
method, implemented in the ape R package, on these 1000
distance matrices. A consensus tree was calculated in Dendro-
scope. The code is available as R package at https://github.com/
lima1/maphylogeny.
Gene expression analysis
We obtained both genome-wide promoter methylation and
gene expression data for 4 NBC and 45 DLBCL samples (13 ABC
and 32 GCB samples). Expression data for NBC were obtained
from GSE15271, generated using Affymetrix HG133_Plus2_mi-
croarray and mas5 normalized together with the expression data
for the DLBCL samples (GSE23501). The processing of RNA,
hybridization, and image scanning were performed as per
Affymetrix protocols. The trimmed mean target intensity of each
array was set to 500. Expression-based classification labels GCB
and ABC were assigned as published in Shaknovich et al. [6]. The
gene expression data for all DLBCLs was deposited to GEO
number GSE23501.
ChIP-on-chip analysis
MYC ChIP-on-chip analysis was performed using Ramos cells.
First, Ramos cells were fixed in 1% formaldehyde for 10 min,
quenched with glycine and washed three times with PBS. Cells
were then resuspended in lysis buffer and sonicated 6630 sec
(amplitude 55%) in an Ultrasonic Dismembrator Model 500
(Fisher) to shear the chromatin to an average length of 500 bp.
Supernatants were precleared using protein-A agarose beads
(Roche) and 10% input was collected. Immunoprecipitation was
performed in 10
7 cells using antibodies against MYC (Santa Cruz).
DNA-protein complexes were pulled down using protein-A
agarose beads and washed. DNA was recovered by overnight
incubation at 65uC to reverse cross-links and purified using
QIAquick PCR purification columns (Qiagen). ChIP products and
their respective input genomic fragments were amplified by
ligation-mediated PCR [43]. Q-ChIP was repeated after ampli-
fication to verify that the enrichment ratios were retained. The
genomic products of three biological ChIP replicates were labeled
with Cy5 (for ChIP products) and Cy3 (for input) and co-
hybridized on a NimbleGen human promoter array representing
1.5 kb of promoter sequence from .24,000 genes (human genome
version 35, May 2004) according to manufacturer’s protocol
(Roche NimbleGen, Inc., Madison, WI). The enrichment for each
promoter was calculated by computing the log ratio between the
probe intensities of the ChIP product and input chromatin, which
were co-hybridized on the same array. Thereafter, for each of the
.24,000 promoter regions, the maximum average log ratio of
three neighboring probes in a sliding window was calculated and
compared with random permutation of the log ratios of all probes
across the entire array. The MYC ChIP-on-chip data is available
on GEO (accession number GSE31110).
The Chip-chip data for BCL6 and EZH2 were previously
published [20,21]. AICDA ChIP-seq data was obtained from the
recently published study in mouse activated B-cells [22] (GEO
accession number GSE24178). Short reads were aligned to the
mm9 genome and ChIP-seq peaks were called using the
ChIPSeeqer program (http://icb.med.cornell.edu/wiki/index.
php/Elementolab/ChIPseeqer_use). Peaks within RefSeq gene
promoters, defined as 4 kb windows centered on transcription start
sites, were then extracted. Human and mouse unambiguous
orthologs were then determined using the reciprocal best BLAST
strategy with protein sequences obtained from RefSeq (and
matched with RefSeq transcripts). Human genes whose mouse
orthologs were associated with 1 or more AICDA peaks in mouse
activated B-cells were then determined.
We obtained CTCF binding site data from InsulatorDB
(http://insulatordb.uthsc.edu; downloaded Jan, 2011), where
CTCF binding sites (CTCF-BS) were determined using ChIP-
on-chip and computational approaches [18,19,44]. We performed
our analysis using experimentally determined CTCF-BS from this
database, and obtained similar results using computationally
predicted CTCF-BS from this database.
All statistical analyses were performed in R.
Supporting Information
Figure S1 Copy number analyses. (A) Distributions of M-scores
against copy number log2 ratios for two GCB and two ABC
samples. (B) Boxplots showing the distributions of M-scores against
copy number loss, gain, and wild type (wt) for those GCB and
ABC samples.
(TIF)
Figure S2 Copy number analyses for frequently amplified or
deleted regions. (A) The distributions of M-scores against copy
number log2 ratios for two GCB and two ABC samples. DNA
promoter methylation probes in the regions that were amplified or
deleted in a given sample, and also overlapped with GISTIC
peaks, are shown in black, and remaining probes are shown in
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PLOS Genetics | www.plosgenetics.org 11 January 2013 | Volume 9 | Issue 1 | e1003137grey. (B) Boxplots showing the distributions of M-scores against
copy number loss, gain, and wild type for those GCB and ABC
samples.
(TIF)
Figure S3 The frequency distribution of (left) the median M-
score and (right) inter-quartile ranges (IQR) of the M-score, per
methylation probe of gene promoters for normal and diseased
samples with $80% purity. The color code is similar to that of
Figure 1A in the main text.
(TIF)
Figure S4 Frequency distribution of M-scores at the genome-
wide methylation probe positions. Data is shown after removal of
low signal to noise ratio probes. Color codes are the same as in
Figure 1.
(TIF)
Figure S5 Scatter plot showing the M-score as reported by the
HELP assay and the percentage DNA methylation as reported by
the RRBS assay for 6 samples. Pearson correlation coefficient (top
right corner) and regression lines are shown for each panel.
(TIF)
Figure S6 MassARRAY validation shows that there is greater
variance in methylation within DLBCL samples than in normal B-
cell samples.
(TIF)
Figure S7 Log(variance ratio) vs. q-value plot demonstrates
greater variance of CpG methylation values derived from
MassARRAY validation. Only 4 CpGs had a lower variance in
DLBCL but the remaining CpGs had a higher variance in
DLBCL as compared to NGC samples. The dashed line on the left
represents equal variance between the two groups. The dashed
line on the right represents 36 higher variance in DLBCL as
compared to NGC.
(TIF)
Figure S8 Technical validation of the HELP array using
MassARRAY Epityping reveals a linear relationship between
these two assays. These validation studies revealed that 1 unit of
log2(HpaII/MspI) change in HELP intensity corresponds to 30%
change in methylation as detected by the MassARRAY.
(TIF)
Figure S9 Distribution of the sites of hypo- and hyper-
methylation along the human chromosomes in both normal and
lymphoma samples. The color code is similar to that of Figure 1A
in the main text.
(TIF)
Figure S10 Distribution of inter-sample standard deviation of
M-score, grouped by NBC, NGC, FL, GCB and ABC. Outliers
are not shown.
(TIF)
Figure S11 Distribution of M-score of the cell lines which
are grouped into three categories – low, intermediate and
high, based on their doubling times. In each panel, the X-axis
represents the M-score, and the Y-axis represents the
frequency of promoter methylation probe sets which have
that M-score. The HELP ID of the cell lines and their
doubling time are provided at the top of each panel. The last
column represents the distribution of the M-score for the
group average. Median and the two quantiles are highlighted
in red.
(TIF)
Figure S12 Distribution of % methylation using the eRRBS
assay at CpG sites in young and old B-cell controls and in
DLBCLs.
(TIF)
Figure S13 Distributions of M-scores at the methylation
probesets overlapping with CpG islands and non-CpG islands
for normal B-cell and DLBCL samples. The color code is as
following: NBC-green, NGC-blue, FL-purple, GCB-red and ABC-
orange. For each sample type, bar width is proportional to the
number of probes with a given M-score, as discussed in details in
Figure 3A in the main text.
(TIF)
Figure S14 Distribution of M-score against CpG density at gene
promoters for NBC, NGC, FL, GCB, and ABC samples. The
regression line for each category is shown in black.
(TIF)
Figure S15 Distribution of the percentage DNA methylation as
estimated for the number of CpG sites in the gene promoters for 6
DLBCL samples. The regression line for each category is shown in
black.
(TIF)
Figure S16 Distribution of (i) |M-score| (y-axis, top) and (ii)
IQR (y axis, bottom) against CpG density at gene promoters for
NBC, NGC, FL, GCB, ABC samples. The regression line for each
category is shown in black.
(TIF)
Figure S17 Distribution of % methylation using the eRRBS
assay at CpG sites in centromeric, telomeric, and intermediate
regions for normal and diseased tissues. In each panel, the vertical
bar represents the median value of the respective distribution.
(TIF)
Figure S18 Kaplan-Meier comparison of the risk stratification
by stage and methylation heterogeneity score (MHS; left) and stage
alone (right) in ABC and GCB.
(TIF)
Figure S19 Kaplan-Meier analysis in ABC only. (A) MHS; (b)
IPI; (c) stage; (d) IPI+MHS; (e) stage+MHS.
(TIF)
Figure S20 Distribution of M-score of the FL samples which are
grouped according to their grades. In each panel, the X-axis
represents the M-score and the Y-axis represents the frequency of
promoter methylation probe sets, which have that M-score. The
HELP ID of the cell lines and their grade are provided at the top
of each panel.
(TIF)
Figure S21 Distributions of M-score for gene-poor, intermedi-
ate, and gene-rich regions for normal and lymphoma samples.
Color codes are the same as in Figure 1. Bar width is proportional
to the number of probes with a given M-score, as discussed in
details in Figure 3A in the main text.
(TIF)
Figure S22 Spreading of aberrant methylation in neighboring
positions. Position ‘‘i’’ represents probes that are significantly
hypo- (black) or hyper-methylated (grey) in lymphoma samples
compared to normal tissues, and ‘‘i6n’’ represents the n
th
neighbors of those probes. The difference in M-score (A and B)
and the difference in between-sample variation, estimated by IQR
(C and D) between the lymphoma and normal samples at ‘‘i’’,
‘‘i61’’, … ‘‘i65’’ positions are shown.
(TIF)
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gene promoters after excluding probesets that map to multiple
genes or genes marked by multiple probesets. Position ‘‘g’’
represents probes that are significantly hypo- (black) or hyper-
methylated (grey) in lymphoma samples compared to normal
tissues, and ‘‘g6n’’ represents the n-th neighboring promoter
probeset. The difference in M-score (A) and the difference in
between-sample variation, estimated by IQR (B) between the
lymphoma and normal samples at ‘‘g’’, ‘‘g61’’, … ‘‘g65’’
positions are shown.
(TIF)
Figure S24 Distributions of M-score for regions with low
CTCF-BS density, intermediate, and high CTCF-BS density in
normal and lymphoma samples. Color codes are the same as in
Figure 1. Bar width is proportional to the number of probes with a
given M-score as discussed in detail in the main text.
(TIF)
Figure S25 Effects of CTCF-binding site on spreading of
aberrant methylation in (left) FL and (right) GCB samples. Locus
‘‘i’’ refers to a promoter probe position that has significantly
different methylation pattern in ABC compared to NGC, and
‘‘i61’’ represent its immediate up- and downstream neighboring
probe positions. Changes in M-score at ‘‘i’’ and ‘‘i61’’ in the
lymphoma samples relative to NGC samples were calculated for
four different scenarios – depending on whether ‘‘i’’ had aberrant
hypo- or hyper-methylation, and presence (black vertical dotted
line) or absence (light grey vertical dotted line) of CTCF-BS
between ‘‘i’’ and ‘‘i+1’’. The horizontal line represents the
genome-wide median D M-score between ABC and NGC
samples. We found that the presence of CTCF-BS restricted the
spreading of aberrant hypo- or hyper-methylation.
(TIF)
Figure S26 Effects of CTCF-binding sites (BS) on the spreading
of aberrant methylation in DLBCL samples. Locus ‘‘i’’ refers to a
promoter probe position that has significantly different methyla-
tion pattern in DLBCL compared to NGC, and ‘‘i61’’ represent
its immediate up- and downstream neighboring positions.
Changes in % methylation at ‘‘i’’ and ‘‘i61’’ in the lymphoma
samples relative to NGC samples were calculated for four different
scenarios – depending on whether ‘‘i’’ had aberrant hypo- or
hyper-methylation, and presence (black vertical dotted line) or
absence (light grey vertical dotted line) of CTCF-BS between ‘‘i’’
and ‘‘i+1’’.
(TIF)
Figure S27 Inter-sample variation, measured using IQR, for the
promoter methylation probe positions of the target genes of
AICDA, BCL6, EZH2, and MYC and also all the promoter probe
positions in our dataset.
(TIF)
Figure S28 Association of promoter methylation of the target
genes of AICDA, BCL6, EZH2, and MYC and transcription
factor gene expression. This association was tested utilizing gene
set analysis (GSA) and the plots (A–C) visualize the GSA results.
The bar plots on the bottom visualize the TF targets in a ranking
by correlation with gene expression, while the plots on the top
visualize the local enrichment, i.e., the deviation from a random
ranking. A positive enrichment score indicates that targets have a
higher (positive) correlation of promoter methylation with
expression than expected by chance. Promoter methylation of
both AICDA and MYC is significantly associated with expression
of BCL6 (panels A and B, respectively), while EZH2 expression is
anti-correlated with its target promoter methylation (C). The
highly similar results in A and B are due to high overlap of targets,
i.e., because many genes are regulated by both MYC and AICDA
(D).
(TIF)
Figure S29 Extent of change in DNA methylation status of
BCL6 (chr3:187 Mb) and MYC (chr8:128 Mb) loci, including the
surrounding genes, in lymphoma samples (FL, GCB and ABC)
compared to that in the normal NBC samples. Blue lines indicate
CTCF binding sites.
(TIF)
Figure S30 Distributions of M-score and inter-sample variation
(IQR) for methylation probes that overlap with common repeat
elements in normal and lymphoma samples. M-scores are shown
on the left and IQR on the right. Color codes are the same as in
Figure 1. Bar width is proportional to the number of probes with a
given M-score as discussed in Figure 3A in the main text. The
dotted horizontal line separates low complexity and simple repeats
from other repeat classes.
(TIF)
Table S1 Patient characteristics.
(PDF)
Table S2 The doubling times of the cell lines used.
(PDF)
Table S3 C-statistic with their standard errors (SE) and 95%
confidence intervals of prognostic models in ABC and GCB
samples. The C-statistic estimates the concordance of the
predictions, which is the probability that in a random pair of
non-censored patients, the one with higher risk relapsed earlier.
(PDF)
Table S4 C-statistics with their standard errors (SE) and 95%
confidence intervals of prognostic models in ABC only.
(PDF)
Text S1 Supporting material.
(DOC)
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